[{"id":"955df77a-df24-4783-84ce-56c74544422c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05003141","created_at":"2021-08-12T13:54:33.131Z","updated_at":"2024-07-02T16:36:14.610Z","phase":"Phase 1a/1b","brief_title":"PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies","source_id_and_acronym":"NCT05003141","lead_sponsor":"Qilu Puget Sound Biotherapeutics (dba Sound Biologics)","biomarkers":" CD20 • CD37","pipe":" | ","alterations":" CD37 expression","tags":["CD20 • CD37"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD37 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PSB202"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 11/15/2021","start_date":" 11/15/2021","primary_txt":" Primary completion: 07/01/2023","primary_completion_date":" 07/01/2023","study_txt":" Completion: 01/01/2024","study_completion_date":" 01/01/2024","last_update_posted":"2022-03-28"},{"id":"bacf0a9a-d80e-41ef-a188-b717b8ce2cef","acronym":"","url":"https://clinicaltrials.gov/study/NCT03343678","created_at":"2021-01-18T16:30:48.751Z","updated_at":"2024-07-02T16:37:15.018Z","phase":"Phase 1","brief_title":"This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax","source_id_and_acronym":"NCT03343678","lead_sponsor":"Boehringer Ingelheim","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • BI 836826"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/17/2018","start_date":" 01/17/2018","primary_txt":" Primary completion: 05/25/2018","primary_completion_date":" 05/25/2018","study_txt":" Completion: 11/25/2020","study_completion_date":" 11/25/2020","last_update_posted":"2018-01-09"}]